RBC Capital raised the firm’s price target on Cidara Therapeutics (CDTX) to $145 from $137 and keeps an Outperform rating on the shares. The company’s CD388 Phase 3 enrollment is already halfway done and on pace for completion in December, potentially enabling readout as early as Q3 should flu event rates fall in line with their projections, the analyst tells investors in a research note. The stock has room for additional meaningful upside, the firm added.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDTX:
- Positive Outlook on Cidara Therapeutics: Progress in CD388 Flu Program and Strategic Trial Advancements
- Cidara Therapeutics Advances CD388 with Phase 3 Expansion
- Cidara Therapeutics reports Q3 EPS ($3.10), consensus ($1.33)
- CDTX Upcoming Earnings Report: What to Expect?
- Cidara Therapeutics’ CD388 Study: A Potential Game-Changer in Influenza Prevention